Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I am sure the period of shareholder value Markku initially talked about has passed with the solvable clever 1 finding and US DoD funding.
He said when asked in the recent Proactive Q&A that Q1 and Q2 would be beneficial for investors and this is what I am waiting for.
He will have known about the recent placing prior to the interview and therefore i agree with Sax that this was a better option to achieve further results into Q2 and then hopefully taking his pick of the best partner
Yes owning Faron shares is quite similar to owning an old classic car ( mine was an MG Midget back in the day ! )
10 months of the year they gather dust , then for 2 months you actually get pleasure from owning them .
Likewise , its about the journey , not the destination ( and wherever you go , it takes longer than planned )
The fuel gauge is a bit sticky , and when you think its empty and tap the dial , it manages to sink even further .
But the owners club is full of cheery folk , and we always wave at each other when we pass !
I always thought mine would make me more attractive to the opposite sex . That never worked , but these shares will if they hit £20 lol
of course, the CEO says it's time to invest, but immediately after that the stock was diluted. I trust the CEO, but we've already painted beautiful pictures of the future. Let's hope at least some medicine can get to the finish line.
The more Clevegen is being used during treatment the more profit for Faron and its partners.
In last proactiv interview Markku clearly said "now is the time to invest on Faron". And that's something I have done.
I'd like to hear also some news from Heamatokine.
Good times ahead!
Appreciate the comments Saxon.
My theory is we should of had shareholder value by now.
Do you remember that that they said clevegen reduced to ours but the the body diluted this out so they are now increasing the amount of Clevegen they are giving... This was what the potential partners were questioning..
I think they need more data points and then the share price will increase once clevegen is proven more up
A square steering wheel, that was the future !
Well put Sax and probably the kindest thing anyone has ever said about the Austin Allegro
When Markku talked of this shareholder value window , I never wrote a date in my diary , as it was a phrase that was put out by Markku as an indication of what he hoped would happen in the near term , given what they knew at the time , and where the company finances were .
This was done before the soluble Clever 1 discovery , and before the recent placing however .
Those Cohorts must be coming along now , and a few must surely now have been fully analysed . To the point at which Markku hinted that shareholders would finally see some action .
What I am undecided at the moment is - was the soluble Clever1 discovery such a 'remarkable' find , that it has made them rethink what they have - hence the placing to carry on trialing before they make any deals ?
I'm not sure , but I'm leaning towards thinking that they now have something even more valuable potentially , and it was worth a further placing to allow them to get some results on the more frequent dosing of Clevegen in trials .
If the trials prove up the theory that Bexmarilimab suppresses soluble Clever1 as well as acting on the solid tumours , then the price tag goes up even further .
Its a shame that the SP always slides back like an Austin Allegro parked on a hill with the handbrake on , and that good news only pushes us up to the place where we started , but we really now are getting into the month or so when the BIG one will land .
We've never been in a situation with so many P2 cohorts coming to completion , and with such positive encouragement from bodies such as the EIC , and the FDA .
Traumakine is doing its thing , and is financially secure now in getting a P3 result one way or another .
Manufacturing of IFN beta1a is coming along well - and regardless of Traumakine - that new manufacturing technique is going to be in high demand .
Clevegen manufacturing also preparing to be scaled up to commercial levels .
This really could be the last chance to lay your hands on some Faron shares at this price ( and I mean that in a good way lol )
Last year (April) Markus mentioned which many of us took notice of the comment ‘significant shareholder value’ with 9 to 12 months. What could be the trigger for that comment , Clevegen news?